A multicenter, open-label, prospective study to investigate immune boost response changes
in patients with metastatic castrate-resistant prostate cancer (mCRPC).
Additional locations may be listed on ClinicalTrials.gov for NCT06134232.
Locations matching your search criteria
United States
California
Duarte
City of Hope Comprehensive Cancer CenterStatus: Active
Name Not Available
Those enrolled in the Booster Study will have had their course of treatment with
PROVENGE® immunotherapy and then randomized to the Booster Study to be treated with a
single booster dose of sipuleucel-T.
Lead OrganizationDendreon Corporation
Principal InvestigatorNadeem Sheikh